MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits
by PR Newswire
Sep 14, 2024 1:32 am
- The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024.
- Encouraging antitumor activity of YL201 in multiple solid tumor types, including SCLC, NPC, and wild-type NSCLC, from Phase I escalation and expansion results.
- In extensive-stage SCLC patients, ORR was 68.1% and mPFS was 6.2 months.
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
ContinueOR
See our subscription options.
Already have an account? Log in here